HealthTree Logo
search more_vert
person Sign In / Create Account
New York Myeloma Roundtable
New York Myeloma Roundtable image
HealthTree Roundtables for Multiple Myeloma
Can't make it to the event?
Sign up and receive the event recording by email

Event Description

Join us for the New York Myeloma Round Table at the New York Marriott at the Brooklyn Bridge, October 19th from 9:00 am-2:30 pm EST to hear from top myeloma researchers. The day includes informative and engaging presentations about the latest in myeloma as well as breakout sessions for both newly diagnosed and relapsed/refractory patients. The event will feature two sessions that include extensive Q&A. Registration opens at 8:00 am.



  • Meeting date: Saturday, October 19, 2024
  • Registration opens at 8:00 am, meeting begins at 9:00 am
  • Location: New York Marriott at the Brooklyn Bridge, 333 Adams Street, Brooklyn, New York
  • Registration, parking, breakfast, lunch and refreshments are free
  • The meeting will be recorded and available to watch at a later time 
  • Nearest Airports: John F Kennedy International Airport (JFK) and Newark Liberty International Airport (EWR)



If you can't make the meeting in person, please register to watch the recording. We will send an email out to all recording registrants about a week following the live meeting.



If you are traveling to the meeting and would like to make a weekend of it while you are in New York, here are some suggestions:



For questions about registration, contact us at +1-800-709-1113 or

For all other questions, contact Elisabeth at


Special Thanks to our Health Tree Round Table for Multiple Myeloma Sponsors!

Schedule & Agenda

The panelist Jennifer Ahlstrom
9:00 AM
Jennifer Ahlstrom
  • Introduction and Meeting Logistics
The panelist Faith Davies, MBBCh, MRCP, MD, FRCPath
Personalizing Myeloma Care Along Your Myeloma Journey
9:15 AM
Faith Davies, MBBCh, MRCP, MD, FRCPath
  • The role of genetics
  • Modern strategies for newly diagnosed patients
  • Using all the tools in the myeloma toolbox
  • The nuances of myeloma care
The panelist Urvi Shah, MD
Nutrition and Myeloma
9:45 AM
Urvi Shah, MD
  • The science of nutrition and cancer
  • Nutrition and precursor condition progression
  • Using real world experiences to drive further data
10:15 AM
The panelist Cesar Rodriguez, MD
Bispecific Antibodies
10:30 AM
Cesar Rodriguez, MD
  • What are bispecific antibodies?
  • Different targets, different approaches
  • How and when to use bispecific antibodies
The panelist Jenny Ahlstrom
HealthTree Cure Hub
11:00 AM
Jenny Ahlstrom
Breakout Sessions
11:15 AM

Saad Usmani, MD - Newly Diagnosed Multiple Myeloma (NDMM) Breakout Session: What Newly Diagnosed patients need to know/SCT in the age of immunotherapies


Sham Mailankody, MD - Relapsed/Refractory Multiple Myeloma (RRMM) Breakout Session: Side effect management for immunotherapies in RRMM

12:00 PM
The panelist Saad Z. Usmani, MD, MBA, FACP
The Future of Myeloma Care
1:00 PM
Saad Z. Usmani, MD, MBA, FACP
  • CAR T therapy and its earlier utility
  • Which myeloma target and when?
  • Immunotherapies and beyond 
Round Table Audience Q&A with Faculty
1:30 PM
Help with HealthTree
2:15 PM
  • Meet the HealthTree team
  • Get educated with HealthTree programs
  • Raffle at 2:15 p.m.

Speakers & Moderators

The panelist Saad Z. Usmani, MD, MBA, FACP
Saad Z. Usmani, MD, MBA, FACP

I am a hematologist-oncologist specializing in the care of patients with multiple myeloma and other disorders affecting plasma cells (the cells that produce the antibodies that protect us against infection). I treat patients who have received a diagnosis of multiple myeloma or a diagnosis of another plasma cell disorder, such as monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or amyloidosis. Many of the patients I see have a disease that has been deemed hard to treat or high risk. A blood cancer diagnosis dramatically changes the trajectory of a patient’s life. I am acutely aware of the impact that I have on a patient’s cancer treatment journey and am passionate about having the opportunity to make a difference in my patients’ lives. Throughout my 14-plus years of caring for patients with multiple myeloma and plasma cell disorders, my patients and their family members have always been the most important people in the room for me. It is my responsibility to educate my patients with relevant information about their disease, alleviate their concerns at each stage in the process, and develop a treatment plan that best befits their individual needs. This is not a responsibility that I take lightly. I am committed to making each of my patients feel comforted in the expertise of their care team and empowered by the information provided to them.

Read Bio
The panelist Sham Mailankody, MBBS
Sham Mailankody, MBBS

I am a medical oncologist specializing in the care of people with multiple myeloma and related plasma cell disorders. With my colleagues at Memorial Sloan Kettering Cancer Center (MSK), I am focused on identifying optimal treatment strategies for people with these disorders. My research focuses on the development of novel immune and cellular therapies, including chimeric antigen receptor (CAR) T cell therapies, for patients with myeloma. I also serve as the Clinical Director of the Cellular Therapy Service and the Research Director of the Myeloma Service at MSK.

Read Bio
The panelist Faith Davies, MBBCh, MRCP, MD, FRCPath
Faith Davies, MBBCh, MRCP, MD, FRCPath

Faith Davies, MBBCh, MRCP, MD, FRCPath, is a member of the faculty of the Department of Medicine at New York University Langone Health and Director of the Clinical Myeloma Program at the Perlmutter Cancer Center. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Her focus is on the biology and treatment of myeloma with an emphasis on potential new drugs and new genetic technologies and their applications to myeloma. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small molecule interventions and translating those laboratory findings into individualized treatment in the clinical setting. Prior to joining NYU Langone Health, Dr. Davies was Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS). She also served as Professor of Medicine and Director of the Phase I Clinical Trials Program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute. Dr. Davies came to UAMS in 2014 from the Institute of Cancer Research and the Royal Marsden Hospital, both in London. She earned her medical degree from the College of Medicine, University of Wales. She completed her general medical training in Cardiff and Birmingham and hematology specialty training in Leeds and London.

Read Bio
The panelist Urvi Shah, MD
Urvi Shah, MD

Dr. Urvi Shah is a faculty on the myeloma service, division of hematologic malignancies at Memorial Sloan Kettering Cancer Center. Her research focuses on studying the role of diet, microbiome, and other lifestyle-related risk factors in plasma cell disorders as well as identifying interventions to improve outcomes for these patients. She also studies immune therapies (including CAR T cell therapies) for myeloma. Being a lymphoma survivor herself she is passionate about helping patients make wise nutritional and lifestyle choices as they face a plasma cell disorder diagnosis as well as raising awareness about healthy choices to prevent cancer.

Read Bio
The panelist Cesar Rodriguez, MD
Cesar Rodriguez, MD

Cesar Rodriguez, MD, recently joined the faculty of Mount Sinai Hospital and is the Clinical and Operations Director of the Myeloma Program for the system. He previously was Associate Professor of Hematology and Oncology at the Wake Forest School of Medicine and led the Myeloma program there for 6 years. His focus is early phase clinical trials, translational medicine using 3D culture models, and immunotherapies. He has led a number of first-in-human studies with bi-specific therapies and has opened the first tri-specific therapy for myeloma targeting NK cells. He is one of three winners of the second Myeloma Crowd Research Initiative (MCRI) competition. His project uses a three-dimensional organoid tumor modeling platform which allows the testing of multiple treatment combinations against a specific tumor to identify which treatments will work best for each individual’s type of myeloma. This personalized approach may help doctors to help find useful drug combinations that will have the most impact and avoid treatments that will be ineffective. Dr. Rodriguez earned his MD at Escuela de Medicina Ignacio A. Santos, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico. He completed his residency at Texas Tech University Health Sciences Center at El Paso and a fellowship at the University of Louisville.

Read Bio
The panelist Jenny Ahlstrom
Jenny Ahlstrom
Lehi, Utah

HealthTree Foundation Founder and President, Blood Cancer Survivor

Read Bio


New York Marriott at the Brooklyn Bridge

333 Adams St, Brooklyn, NY 11201, USA

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube